Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Con

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. SPY
4. IQMX
5. MSTR
6. EROC
7. SEER
8. NVDA
9. RIVN
10. TSLA

Go back to Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Con
(NASDAQ: ALLO) Delayed: 2.09 +0.01 (0.48%)
Previous Close $2.08    52 Week High $ 
Open $2.08    52 Week Low $ 
Day High $2.16    P/E N/A 
Day Low $2.07    EPS $ 
Volume 10,911,773